| abstract |
The present invention relates to fused tricyclic compounds or its tautomer, polymorphic form, steric isomer, prodrug, solvate or the pharmacological-acceptable salt of formula (I), or comprise their pharmaceutical composition, and the methods for the treatment of of the patient's condition mediated as A2A adenosine receptor antagonists by it and disease.n compound of the present invention can the disease of improvement and disorder easily through adenosine A 2 A receptor mediation in treatment, prevention or suppression.This type of patient's condition comprises, but be not limited to, Parkinson's disease, restless leg syndrome, alzheimer disease, nerve degenerative diseases, inflammation, wound healing, fibrosis of skin, Nocturnal myoclonus, cerebral ischemia, myocardial ischemia, Huntington Chorea, multiple system atrophy, corticobasal degeneration, Wilson's disease or cause other basal nucleis dyskinetic disorderly, posttraumatic stress disorder, liver cirrhosis, Sepsis, Spinal injury, retinopathy, hypertension, Social Memory defect, dysthymia disorders, neuroprotective, narcolepsy or other sleep associated with disease, attention deficit hyperactivity disorder, dopy, posttraumatic stress disorder and blood vessel injury etc.The invention still further relates to the preparation method of this compounds, and relate to the pharmaceutical composition comprising them. |